Esperion Therapeutics (NASDAQ:ESPR) Posts Earnings Results, Misses Estimates By $0.06 EPS

Esperion Therapeutics (NASDAQ:ESPR) posted its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06), FiscalAI reports. The company had revenue of $80.10 million for the quarter, compared to analysts’ expectations of $84.52 million.

Esperion Therapeutics Price Performance

NASDAQ ESPR remained flat at $3.14 during trading hours on Friday. 7,422,727 shares of the company traded hands, compared to its average volume of 8,629,511. Esperion Therapeutics has a one year low of $0.69 and a one year high of $4.18. The company has a market cap of $808.25 million, a P/E ratio of -18.47, a PEG ratio of 2.56 and a beta of 0.91. The company’s 50-day moving average is $2.53 and its 200-day moving average is $3.09.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ESPR. Needham & Company LLC lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. HC Wainwright lowered Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price objective on the stock. in a report on Friday, May 1st. Piper Sandler lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Finally, Cantor Fitzgerald downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.54.

Institutional Trading of Esperion Therapeutics

Institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp acquired a new position in Esperion Therapeutics during the first quarter worth $278,000. Sivia Capital Partners LLC acquired a new stake in Esperion Therapeutics during the 2nd quarter worth approximately $25,000. Geode Capital Management LLC boosted its position in Esperion Therapeutics by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company’s stock valued at $4,513,000 after buying an additional 137,691 shares during the period. Rhumbline Advisers grew its stake in shares of Esperion Therapeutics by 16.8% in the second quarter. Rhumbline Advisers now owns 275,688 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 39,658 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Esperion Therapeutics by 93.3% during the 2nd quarter. Invesco Ltd. now owns 493,929 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 238,449 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.